No Data
No Data
CSPC Pharma (01093.HK) plans to hold a board of directors meeting on August 21 to approve its mid-term performance.
CSPC Pharma (01093.HK) announced that the board of directors meeting will be held on August 21, 2024 (Wednesday) to approve the unaudited interim performance of the company and its subsidiaries for the six months ended June 30, 2024.
CSPC Pharma (01093): The first CAR-T cell injection based on mRNA-LNP, SYS 6020, has been approved for new indications in clinical trials.
CSPC Pharma (01093) announced the development of its first mRNA-LNP-based product targeting B cells...
Express News | CSPC Pharmaceutical - Obtained Approval From Nmpa of China
Express News | CSPC Pharmaceutical - First Mrna-Lnp-Based CAR-T Cell Injection (Sys6020) Obtains Clinical Trial Approval for New Indication
CSPC PHARMA: DATE OF BOARD MEETING
CSPC Pharma (01093) receives approval for Class 1 CAR-T therapy clinical trial.
On August 9th, China National Medical Products Administration's Center for Drug Evaluation (CDE) website revealed that CSPC Pharma (01093) has applied for class 1 new drug approval for SYS6020 injection, intended for the treatment of refractory active systemic lupus erythematosus.
No Data